Michael Mollerus

Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…

Davis Polk is advising the dealer managers in connection with cash tender offers by ERP Operating Limited Partnership, an operating partnership subsidiary of Equity Residential (the …

Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of Cempra, Inc. The net proceeds to Cempra were approximately $93.7…

Davis Polk is advising Charles River Laboratories International, Inc. on its acquisition of WIL Research for approximately $585 million. The transaction, which is expected to close early in…

Davis Polk is advising Communications Sales & Leasing, Inc. on its acquisition of PEG Bandwidth, LLC from affiliates of Associated Partners, L.P. and certain other sellers. The purchase…

Davis Polk advised the representatives of the underwriters on an SEC-registered offering by BankUnited, Inc. of $400 million aggregate principal amount of 4.875% senior notes due 2025…

Davis Polk advised the representative of the several initial purchasers in a Rule 144A/Regulation S offering by Huntington Ingalls Industries, Inc. of $600 million aggregate principal…

Davis Polk is advising C1 Financial, Inc. (“C1”) on its acquisition by Bank of the Ozarks, Inc. (“OZRK”). Upon the closing of the transaction, C1 and its wholly owned subsidiary, C1 Bank,…

Davis Polk advised representatives to the initial purchasers in connection with a Rule 144A and Regulation S offering by Terrafina of $425 million aggregate principal amount of 5.250%…

Davis Polk advised underwriters in connection with a public offering by International Business Machines Corporation of $900 million principal amount of its 2.875% notes due 2022. The Davis…